Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...
Verywell Health on MSN2mon
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant DepressionThe Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a ...
The nasal spray had to go through many rounds of clinical testing, with some shown to improve depression, while others showed no improvement over a placebo. In 2019, the FDA approved Spravato for ...
Hosted on MSN2mon
FDA-Approved Nasal Spray For Depression Is First Of Its KindA ketamine-based nasal spray is officially the first and ... the agency has now decided the Spravato spray can be used on its own. The training wheels are essentially off. Patients eligible ...
Spravato is approved as an adjunctive therapy administered by a nasal spray and is based on esketamine, a form of the drug ketamine, an anaesthetic commonly used illegally for recreational purposes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback